ArticleBlood vessels, thrombosis & hemostasis2026
Social vulnerability, access to care, and outcomes in hemophilia.
Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in hemophilia management and outcomes, inequities remain for socially vulnerable populations. This cross-sectional study examined the association between the social vulnerability index (SVI), a composite measure of community vulnerability, and health outcomes among people with hemophilia (PwH) who received treatment across 137 hemophilia treatment centers (HTCs) and were enrolled in the Community Counts Registry between 2013 and 2022. Participants' overall percentile SVI rank was based on their zip codes and grouped as low (0-0.33), medium (>0.33-0.66), or high (>0.66-1.0); higher scores corresponded to higher vulnerability. Adjusted odds ratios (aOR) with 95% confidence intervals (CI) were used to assess SVI, treatment, and outcomes. Among 14 074 PwH, 31.7%, 42.7%, and 25.5% were categorized as having low, medium, and high SVI, respectively, at enrollment. A higher proportion of Black (20.8%) and Hispanic (33.0%) participants were in the high vs medium (Black 9.4%, Hispanic 14.2%) or low (Black 4.8%, Hispanic 8.8%) SVI groups. Compared with participants with low SVI, those with high SVI had higher odds of treated bleeds (aOR, 1.09; 95% CI, 1.02-1.16), intracranial hemorrhage (aOR, 1.22; 95% CI, 1.04-1.42), inpatient admission (aOR, 1.40; 95% CI, 1.28-1.52), emergency department visits (aOR, 1.27; 95% CI, 1.20-1.34), chronic pain (aOR, 1.20; 95% CI, 1.14-1.26), limited physical function (aOR, 1.24; 95% CI, 1.18-1.31), and missed days from school/work (aOR, 1.13; 95% CI, 1.05-1.21) and were less likely to be on extended half-life products (aOR, 0.90; 95% CI, 0.83-0.97) or emicizumab (aOR, 0.78; 95% CI, 0.72-0.84). In this nationwide study of PwH who were treated at US HTCs, those with a high SVI had inferior clinical outcomes, worse quality of life, and less-optimized care. Strategies are needed to mitigate social vulnerability beyond hemophilia clinics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.